SCHEMBL3535002

SCHEMBL3535002

CC(C)(C)OC(=O)NC1CCN(c2cc(-c3ccccc3C(F)F)ncn2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB2 P05107 4/20 0.56
ICAM1 P05362 4/20 0.56
ITGAL P20701 4/20 0.56
CKS1B P61024 1/20 0.52
SKP1 P63208 1/20 0.52
SKP2 Q13309 1/20 0.52
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.46
SUV39H2 Q9H5I1 4/20 0.43
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
OGFRL1 Q5TC84 1/20 0.41
PDE10A Q9Y233 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
RET P07949 1/20 0.40
SSTR4 P31391 1/20 0.40
MAP4K4 O95819 2/20 0.40
KCNA3 P22001 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4607309 0.86 CYP1A2 (0.43) ITGB2ICAM1ITGALCKS1BSKP1
SCHEMBL3527603 0.85 CNR1 (0.48) ITGB2ICAM1ITGALCNR1CNR2
SCHEMBL3534646 0.84 CKS1B (0.56) ITGB2ICAM1ITGALCKS1BSKP1
SCHEMBL28381103 0.83 CKS1B (0.56) ITGB2ICAM1ITGALCKS1BSKP1
SCHEMBL12990834 0.79 CKS1B (0.50) ITGB2ICAM1ITGALCKS1BSKP1
SCHEMBL8512837 0.77 CKS1B (0.55) ITGB2ICAM1ITGALCKS1BSKP1
SCHEMBL2273395 0.77 CKS1B (0.55) ITGB2ICAM1ITGALCKS1BSKP1
SCHEMBL2277215 0.76 CKS1B (0.53) ITGB2ICAM1ITGALCKS1BSKP1
SCHEMBL4622343 0.76 LRRK2 (0.38) ITGB2ICAM1ITGALCYP1A2CYP2C19
SCHEMBL13472399 0.75 CKS1B (0.56) ITGB2ICAM1ITGALCKS1BSKP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 US disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 US disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels KCNJ1, KCNJ2, KCNJ11 ITGB2 4649/4885ICAM1 4095/4885ITGAL 4656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.